Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease

Proceedings of the American Thoracic Society

Volumn 8, Issue 4, 2011, Pages 356-362

  Han, MeiLan K ^a   Martinez, Fernando J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

COPD; Exacerbation; Inflammation; Novel; Therapeutics

Indexed keywords

ACETYLCYSTEINE; AZITHROMYCIN; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CURCUMIN; CYSTEINE DERIVATIVE; ERYTHROMYCIN; FLUTICASONE; FORMOTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INFLUENZA VACCINE; INTERLEUKIN 8 ANTIBODY; IPRATROPIUM BROMIDE; MACROLIDE; MOXIFLOXACIN; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PNEUMOCOCCUS VACCINE; QUERCETIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REACTIVE OXYGEN METABOLITE; RESVERATROL; RIBOFLAVIN; ROFLUMILAST; S CARBOMETHYLCYSTEINE; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; HEALTH CARE COST; HUMAN; INFECTION; INFECTION PREVENTION; INFLUENZA; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW (TOPIC); VACCINATION;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BRONCHODILATOR AGENTS; HUMANS; PNEUMONIA, BACTERIAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VACCINATION;

EID: 80051757118     PISSN: 15463222     EISSN: 19435665     Source Type: Journal    
DOI: 10.1513/pats.201102-016RM     Document Type: Conference Paper

References (75)

1. Anzueto A, Sethi S, Martinez F. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:554-564. (Pubitemid 47547851)
2. Celli B, Barnes P. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007;29:1224-1238. (Pubitemid 46895385)
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555. (Pubitemid 47403272)
4. Celli B, MacNee W, and committee members; ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
5. Martinez F, Han M, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect Ther 2006;4:101-124.
6. Huang Y, Kim E, Cox M, Brodie E, Brown R, Wiener-Kronish J, Lynch S. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS 2010; 14:9-17.
7. Sethi S, Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355-2365.
8. Curtis J, Freeman C, Hogg J. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc 2007;4:512-521. (Pubitemid 47547845)
9. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789. (Pubitemid 46294610)
10. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-1554.
11. Niewoehner D, Rice K, Cote C, Paulson D, Cooper J Jr, Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-326.
12. Van den Bruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a metaanalysis. BMC Pulm Med 2010;10:50.
13. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171-1178.
14. Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson TJ, Smith B, Muhammad J. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;3:CD006101.
15. Nannini L, Cates C, Lasserson T, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting betaagonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4.
16. Rodrigo G, Castro-Rodriguez J, Plaza V. Safety and efficacy of combined long-acting b-agonists and inhaled corticosteroids vs longacting b-agonists monotherapy for stable COPD: a systematic review. Chest 2009;136:1029-1038.
17. Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, Yates JC, Jones PW. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J; 5:44-49.
18. Singh S, Amin A, Loke Y. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-229.
19. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-647.
20. Sin DD, Tashkin D, Zhang X, Radner F, Sjobring U, Thoren A, Calverley PM, Rennard SI. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374:712-719.
21. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE. Efficacy and tolerability of budesonide/ formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009;69:549-565.
22. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008;68:1975-2000.
23. Calverley P, Stockley R, Seemungal T, Hagan G, Willits L, Riley J, Wedzica J, on behalf of the INSPIRE investigators. Reported pneumonia in COPD: findings from the inspire study. Chest(In press)
24. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, et al. Tiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-555. (Pubitemid 351650535)
25. Spina D. Pde4 inhibitors: current status. Br J Pharmacol 2008;155:308-315.
26. Rabe K, Bateman E, O'Donnell D, Witte S, Bredenbroker D, Bethke T. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366:563-571.
27. Calverley P, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri L. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-161.
28. Rennard S, Claverley P, Goehring U, Bredenbroker D, Martinez F. Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18.
29. Calverley P, Rabe K, Goehring U, Kristiansen S, Fabbri L, Martinez F. M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-694.
30. Fabbri L, Calverley P, Izquierdo-Alonso J, Bundschuh D, Brose M, Martinez F, Rabe K. M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703.
31. Han M, Augusti A, Calverley P, Celli B, Criner G, Curtis J, Fabbri L, Goldin J, Jones P, MacNee W, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598-604.
32. Staykova T, Black P, Chacko E, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2001; CD004105.
33. Martinez F, Curtis J, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J COPD 2008;3:331-350.
34. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998;113:1542-1548. (Pubitemid 28307157)
35. Monso E, Garcia-Aymerich J, Soler N, Farrero E, Felez MA, Anto JM, Torres A. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect 2003;131:799-804. (Pubitemid 37062902)
36. Wagner T, Soong G, Sokol S, Saiman L, Prince A. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 2005;128:912-919. (Pubitemid 41140526)
37. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995;99:26S-30S. (Pubitemid 26061985)
38. Takeoka K, Ichimiya T, Yamasaki T, Nasu M. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with pseudomonas aeruginosa in biofilm. Chemotherapy 1998; 44:190-197. (Pubitemid 28204181)
39. Kawamura-Sato K, Iinuma Y, Hasegawa T, Horii T, Yamashino T, Ohta M. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother 2000;44:2869-2872.
40. Suzuki T, Yanai M, Yamaya M, Satoh-Nakagawa T, Sekizawa K, Ishida S, Sasaki H. Erythromycin and common cold in COPD. Chest 2001;120: 730-733. (Pubitemid 32885442)
41. Gomez J, Banos V, Simarro E, Lorenzo Cruz M, Ruiz Gomez J, Latour J, Garcia Martin E, Canteras M, Valdes M. [Prospective, comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD]. Rev Esp Quimioter 2000;13:379-383.
42. Seemungal T, Wilkinson T, Hurst J, Perera W, Sapsford F, Wedzicha J. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-1147.
43. Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, Wilson R. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010;11:10.
44. Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, Merino M, Perez J, Lima J. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61:189-195.
45. Davis AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease: a pilot study. Chest 1987;92: 204-212. (Pubitemid 17118565)
46. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 1987;136:361-365. (Pubitemid 17015980)
47. Steentoft J, Konradsen HB, Hilskov J, Gislason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease: the effect of ongoing, systemic steroid treatment. Vaccine 2006;24:1408-1412. (Pubitemid 43222051)
48. Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, Scanlon PD, Woodruff PG, Washko GR, Connett JE, et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:499-505.
49. Cazzola M, Rogliani P, Curradi G. Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. Respir Med 2008;102:321-327.
50. Tandon M, Phillips M, Waterer G, Dunkley M, Comans P, Clancy R. Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest 2010;137:805-811.
51. Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004;125:2011-2020. (Pubitemid 38788164)
52. Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. J Med Assoc Thai 2003;86:497-508. (Pubitemid 37039541)
53. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999;159:2437-2442. (Pubitemid 29526772)
54. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999;19: 2894-2900. (Pubitemid 30029815)
55. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM III, Trocha SD, Huang PL, Smith MB, Lefer AM, Lefer DJ. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein e-deficient mice. Circulation 2001;103:2598-2603. (Pubitemid 32521971)
56. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S. Lipophilic HMGCo-A reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator- activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000;67:863-876. (Pubitemid 30491080)
57. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-1217.
58. Blamoun AI, Batty GN, DeBari VA, Rashid AO, Sheikh M, Khan MA. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008;62:1373-1378.
59. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensinconverting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-2560. (Pubitemid 43866389)
60. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279-283. (Pubitemid 46237383)
61. Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kinasewitz GT. The use of statins and lung function in current and former smokers. Chest 2007;132:1764-1771.
62. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest 2009;136:734-743.
63. de Boer WI, Yao H, Rahman I. Future therapeutic treatment of COPD: struggle between oxidants and cytokines. Int J Chron Obstruct Pulmon Dis 2007;2:205-228.
64. Rahman I, MacNee W. Role of transcription factors in inflammatory lung diseases. Thorax 1998;53:601-612. (Pubitemid 28335523)
65. Poole P, Black P. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; CD001287.
66. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001;322: 1271-1274. (Pubitemid 32493959)
67. Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, et al. Effects of n-acetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on nac cost-utility study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365:1552-1560. (Pubitemid 40615404)
68. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev 2010;19:127-133.
69. Puchelle E, Aug F, Polu JM. Effect of the mucoregulator s-carboxymethyl- cysteine in patients with chronic bronchitis. Eur J Clin Pharmacol 1978;14:177-184. (Pubitemid 9041035)
70. Colombo B, Turconi P, Daffonchio L, Fedele G, Omini C, Cremaschi D. Stimulation of cl- secretion by the mucoactive drug scarboxymethylcysteine- lysine salt in the isolated rabbit trachea. Eur Respir J 1994;7:1622-1628. (Pubitemid 24294247)
71. Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, Bai CX, Wang CZ, Wang C, Chen BY, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (peace study): a randomised placebo-controlled study. Lancet 2008;371: 2013-2018. (Pubitemid 351799858)
72. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004;364:985-996. (Pubitemid 39208462)
73. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J,Mahler D, Saadeh C, Siler T, Snell P, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926-934. (Pubitemid 46684703)
74. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004;126:926-934. (Pubitemid 39258050)
75. Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development. Drug Discov Today 2007;12:479-486. (Pubitemid 46795591)